Syros Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Syros Pharmaceuticals is Conley Chee, benoemd in Dec2023, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.04M, bestaande uit 46% salaris en 54% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.49% van de aandelen van het bedrijf, ter waarde € 36.86K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 11.6 jaar.

Belangrijke informatie

Conley Chee

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris	46.0%
Dienstverband CEO	less than a year
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	11.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Conley Chee's beloning veranderd ten opzichte van Syros Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

Compensatie versus markt: De totale vergoeding ($USD 1.04M ) Conley } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Conley te vergelijken met de prestaties van het bedrijf.

CEO

Conley Chee (54 yo)

less than a year

Tenure

US$1,041,697

Compensatie

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% € 36.9k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	no data	US$82.15k	0.040% € 3.0k
Jason Haas	Chief Financial Officer	3.1yrs	US$833.02k	0% € 0
David Roth	Chief Medical Officer	8.9yrs	US$876.53k	0% € 0
James Bradner	Founder	no data	geen gegevens	geen gegevens
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	2.1yrs	US$1.46m	0% € 0
Lisa Roberts	Vice President of Human Resources	1.8yrs	geen gegevens	geen gegevens
Kristin Stephens	Chief Development Officer	4.4yrs	geen gegevens	0% € 0

2.6yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0S90 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% € 36.9k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	US$82.15k	0.040% € 3.0k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens
Peter Karl Wirth	Independent Chairman	7.8yrs	US$110.40k	0.060% € 4.5k
Mark Murcko	Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens
Nancy Simonian	Director	11.6yrs	US$1.49m	0.66% € 49.5k
Gerard Evan	Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens
Scott Biller	Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens
Bradley Bernstein	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stefan Knapp	Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens
Aviv Regev	Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens
Chris Vakoc	Member of Scientific Advisory Board	11.6yrs	geen gegevens	geen gegevens

11.6yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0S90 zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.6 jaar).

Syros Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chief Financial Officer recently bought €146k worth of stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Insider recently bought €108k worth of stock

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought €146k worth of stock

New minor risk - Profitability

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022)

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Forecast to breakeven in 2026

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022)

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022)

Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021)

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021)

Insufficient new directors

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought €108k worth of stock

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021)

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021)

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020)

New 90-day low: €6.60

Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019)

Revenue beats expectations

Syros Pharmaceuticals, Inc. announced that it has received $20 million in funding from Oxford Finance LLC

New 90-day high: €8.75

Syros Pharmaceuticals, Inc. Announces the New Clinical Data from its Phase 2 Trial Evaluating SY-1425

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Syros Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €6.50